Business Details
38 Years
experience
Pioneering Biotechnology Innovation
Regeneron Pharmaceuticals is a pioneering biotechnology company dedicated to transforming scientific discoveries into life-changing medicines for patients with serious diseases. Founded in 1988 by physician-scientists, our mission centers on relentless innovation in research and development, leveraging proprietary technologies like the VelociSuite platform to create optimized fully human antibodies and bispecific antibodies. Our approach integrates cutting-edge genetic research through the Regeneron Pharmaceuticals Genetics Center, which has sequenced over 3 million exomes to identify novel therapeutic targets. With a 35-year legacy of translating science into medicine, we have developed 14 FDA-approved treatments and maintain a robust pipeline of ~45 product candidates across multiple therapeutic areas. Our commitment extends beyond the lab, prioritizing environmental sustainability, community impact, and ethical business practices that align with global responsibility goals.Headquartered in Tarrytown, NY, we operate globally with 15,100+ employees across 12 countries and clinical trials in over 50 nations. Recognized for scientific excellence, we rank among Science magazine's top employers and maintain leadership positions in sustainability indices. Our collaborative approach to drug development partners advanced technologies with strategic alliances to accelerate medical breakthroughs. From rare diseases to oncology, our work redefines treatment paradigms through data-powered insights and genetic medicine platforms. This unwavering focus on patients over profits drives our pursuit of scientific excellence and transformative healthcare solutions.
Services
Biologics Development
Genetic Medicine Platforms
Antibody Discovery
Clinical Research
Drug Commercialization
Genomic Sequencing
Oncology Treatments
Rare Disease Therapies
Immunology Research
Sustainability Initiatives
Details
- Year established: 1988
Highlights and features
- We've developed 14 FDA-approved medicines through proprietary VelociSuite antibody technologies
- Our Regeneron Pharmaceuticals Genetics Center has sequenced over 3 million exomes for target discovery
- We maintain a 100% in-house drug candidate development success rate
- Recognized 6 consecutive years on the Dow Jones Sustainability World Index
- Ranked #1 biopharma employer by Science magazine for 7 consecutive years
Services
Biologics Development
Our biologics development leverages proprietary VelociSuite technologies to create optimized fully human antibodies and bispecific antibodies. This platform enables rapid translation of scientific discoveries into targeted therapies for conditions like cancer and autoimmune diseases. With 14 FDA-approved treatments, our approach combines genetic insights with advanced protein engineering to address complex medical needs.
Genetic Medicine Platforms
Genetic medicine platforms integrate the Regeneron Pharmaceuticals Genetics Center's 3 million+ exome sequencing database with CRISPR genome editing capabilities. This enables identification of novel therapeutic targets and development of precision treatments for rare and common diseases. Our work has uncovered protective gene mutations like GPR75 for obesity research.
Clinical Research
Clinical research spans ~45 product candidates across 10 therapeutic areas, including oncology and ophthalmology. Our trials operate in over 50 countries, following rigorous protocols that led to first-in-class treatments like the Ebola antibody cocktail. We maintain 100% in-house development success from discovery through FDA approval.
Antibody Discovery
Antibody discovery utilizes VelocImmune technology to generate fully human monoclonal antibodies. This platform produced Dupixent for type 2 inflammatory diseases and Libtayo for cancer immunotherapy. Our approach combines transgenic mouse models with high-throughput screening to accelerate therapeutic development.
Drug Commercialization
Drug commercialization encompasses end-to-end operations from manufacturing to market access. With $7 billion invested in US production facilities, we ensure scalable supply of approved therapies. Our approach maintains strict quality controls while expanding treatment availability through global partnerships and patient assistance programs.
People
Leonard S. Schleifer
Co-Founder, President, CEO & Co-Chair
Neurologist-scientist who co-founded Regeneron Pharmaceuticals in 1988. Leads strategic vision and scientific direction while championing STEM education initiatives. Holds MD/PhD from NYU and has received Ernst & Young's Entrepreneur of the Year award.
George D. Yancopoulos
Co-Founder, President, CSO & Co-Chair
Immunologist-geneticist who joined Regeneron Pharmaceuticals in 1989. Pioneered VelociSuite technologies and leads scientific innovation. Holds MD/PhD from Columbia University and was named one of the world's most highly cited scientists in 1999.
Aris Baras
Senior Vice President & Head, Regeneron Genetics Center
Physician-geneticist overseeing the center's decade-long impact in human genetics research. Leads initiatives sequencing 3 million+ exomes to identify novel therapeutic targets like GPR75 for obesity and metabolic diseases.
Questions
What diseases does Regeneron Pharmaceuticals focus on treating?
We target serious conditions across 10 therapeutic areas including cancer, eye diseases, allergic/inflammatory disorders, cardiovascular diseases, and rare genetic conditions through biologics and genetic medicine platforms.
How does Regeneron Pharmaceuticals develop new medicines?
Our proprietary VelociSuite platform enables rapid antibody development while the Regeneron Pharmaceuticals Genetics Center uses genomic insights to identify novel targets. This combined approach accelerates drug discovery from bench to bedside.
Where are Regeneron Pharmaceuticals's research facilities located?
Our global headquarters and primary R&D operations are in Tarrytown, NY with additional facilities in Rensselaer, NY and international locations across Europe, Asia, and Canada.
What sustainability initiatives does Regeneron Pharmaceuticals have?
We've achieved 100% waste diversion from landfills, surpassed 2025 environmental goals, and maintain leadership positions in global sustainability indices through energy-efficient operations and green manufacturing practices.
How can patients access Regeneron Pharmaceuticals treatments?
Our medicines are available through traditional distribution channels. We also offer patient assistance programs and work with healthcare providers to ensure appropriate access to FDA-approved therapies for eligible patients.
Videos
Reviews (5)
C. H.
Oct 12, 2020
Report
World Class Company!!! PhDs, scientists, well educated professionals, and others, find a career here! Check out their job site. I have followed the Regeneron history from 1990. The stock then was $4. Now it's in the mid $300 and went as high as $600. I have the distinct honor of knowing one of the principles of this company since 1990 and his family. This company has grown a 1000 fold and those who work there truly appreciate the scientific research and expansion of drugs to help mankind. They are unparalleled in their efforts to make employees feel they have a home. Their wages are good and their
Lester Fung
Oct 04, 2020
Report
It's the first time for everything which makes it challenging and adventurous. If you have a passion for doing good and doing well you will always be happy for working at a company that cares about its employees! A big happy family helping each other for the common good for humanity.
T. Fujita
Dec 30, 2019
Report
If you want to use Google Map to guide you there, it's better to use the company name to set the destination, not the 777 address.
Joey Maddox
Dec 22, 2019
Report
I work for a business that needed assistance, and never in my career have i ever dealt with a switchboard operator so rude before. I understand people have bad days, but to completely take it out on an associate from another business, is the most unprofessional way to deal with personal issues.
Mike Wu
Dec 04, 2018
Report
"Doing Well by Doing Good"
Regeneron is one of the best pharmaceutical companies, if not the best, period. The company cares about their employees, and the employees care about the people they're trying to help by developing new medicines. Research is cutting edge and people are given the tools necessary to make breakthroughs and the friendly work environment to be motivated to continue to do good work. Community service and charity events are quite common. Regeneron and its people care, and their passion and goodwill shows through the work that they do. Being able to work or intern here is truly
Regeneron is one of the best pharmaceutical companies, if not the best, period. The company cares about their employees, and the employees care about the people they're trying to help by developing new medicines. Research is cutting edge and people are given the tools necessary to make breakthroughs and the friendly work environment to be motivated to continue to do good work. Community service and charity events are quite common. Regeneron and its people care, and their passion and goodwill shows through the work that they do. Being able to work or intern here is truly
